Company Profile

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

Employees

Sector

Biotechnology & Medical Research

More about the company

03/06/24	Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	MT
03/06/24	Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	CI
29/05/24	Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	MT
29/05/24	Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/05/24	Aeterna Zentaris Finalizes Some Details for Ceapro Merger	MT
17/05/24	Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	MT
29/04/24	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/04/24	Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
28/03/24	Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	MT
28/03/24	Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	MT
27/03/24	Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	MT
27/03/24	Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	MT
27/03/24	Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	MT

03/06/24	Aeterna Zentaris and Ceapro Complete Merger Transaction	GL
03/06/24	Aeterna Zentaris and Ceapro Complete Merger Transaction	AQ
03/06/24	Canadian Investment Regulatory Organization Trading Halt - CZO	AQ
29/05/24	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	AQ
29/05/24	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	GL

Manager	Title	Age	Since
Gilles Gagnon CEO	Chief Executive Officer	72	21/06/2012
Giuliano La Fratta DFI	Director of Finance/CFO	-	-
Michael Teifel CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Gilles Gagnon BRD	Director/Board Member	72	01/01/2007
William Li BRD	Director/Board Member	63	20/11/2014
Ulrich Kosciessa BRD	Director/Board Member	-	28/04/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/6/24	Geneviève Foster	Marche	Director	210,000	0.2682%
7/6/24	Ulrich Kosciessa	Marche	Director	230,000	0.2938%
7/6/24	Gilles Gagnon	Marche	Chief Executive Officer	700,000	0.8941%

Ceapro Inc. Stock

Stocks

CZO

CA1499071076

Biotechnology & Medical Research

Latest news : Ceapro Inc.

Press Releases: Ceapro Inc.

News in other languages: Ceapro Inc.

Quotes and Performance

Managers and Directors: Ceapro Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CEAPRO INC.	-11.76%	-16.67%	-	-	12.8M
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	43.61B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.77B
Average	+0.73%	+6.32%	+85.64%	+116.60%	29.39B
Weighted average by Cap.	+2.54%	+6.10%	+104.25%	+140.79%